Johnson & Johnson on Jan. 24 posted $23.7 billion in 2022 revenue, a 4.4 percent decrease. Its orthopedic sales remained flat year-over-year, and its fourth-quarter orthopedic sales fell slightly.
Five things to know:
1. Orthopedic sales in the fourth quarter was $2.1 billion, a 0.4 percent decrease. Hip sales rose 1.7 percent year-over-year in the fourth quarter with $385 million, and knee sales grew 3.4 percent with $354 million.
2. Fourth quarter trauma sales fell 2.4 percent year-over-year with $710 million. The spine and sports medicine segments saw $699 million in fourth qarter sales, a 1.3 percent year-over-year decrease.
3. Full-year orthopedic sales of $8.6 billion was the same compared to 2021 sales.
4. MedTech business as a whole brought in $6.8 billion on 2022, a 1.2 percent decrease from 2021.
5. Johnson & Johnson expects 2023 operational revenue to grow 3.5 percent.